Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jamjoom Pharmaceuticals Factory Company (4015.SR)
SAR148.90
+3.90 (+2.69%)
SA SAU Healthcare Drug Manufacturers - Specialty & Generic
Address
Industrial Area 21442
Jeddah, Makkah Province, SA
Jeddah, Makkah Province, SA
CEO
Tarek Youssef Hussein Hosni
Website
jamjoompharma.com
IPO
2023-06-20
ISIN SA15QGU1UNH6
Description
Established in 1994, Jamjoom Pharmaceuticals Factory Company, headquartered in Jeddah, Saudi Arabia, is a key player in the production and commercialization of medicinal products. The firm serves markets both within the Kingdom of Saudi Arabia and across various international regions. Its extensive product portfolio addresses a wide array of therapeutic needs, covering ophthalmology, dermatology, gastrointestinal issues, cardiovascular health, central nervous system disorders, as well as general medicine, over-the-counter remedies, and nutraceuticals/consumer health products.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SAR148.90
+3.90 (+2.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
43.7K
Beta
0.28
Float Shares
27.37M
Free Float %
39.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -1.29% | +14.73% | +1.46% | +7.80% | -11.84% | +96.67% | +96.67% | +96.67% | +96.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
148.90
DCF (Unlevered)
130.28
-12.5%
DCF (Levered)
216.75
+45.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
25% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 3 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
19.78
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
9 / 10
Strong MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+13.8% ★ Q1'26: +5.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+29.4% ★ Q1'26: +7.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+31.6% ★ Q1'26: -0.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+31.6% ★ Q1'26: +35.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%—
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.4% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×— Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
916.67M
est: 1.03B (-11.4%)
|
1.10B
est: 1.23B (-10.7%)
|
1.32B
est: 1.32B (-0.3%)
|
1.50B
est: 1.50B (+0.3%)
|
1.63B
1.63B – 1.63B
+9.2% YoY
|
1.86B
1.86B – 1.86B
+13.9% YoY
|
2.07B
2.07B – 2.07B
+10.9% YoY
|
2.33B
2.33B – 2.33B
+12.6% YoY
|
| EBITDA |
211.16M
est: 310.30M (-31.9%)
|
342.54M
est: 369.62M (-7.3%)
|
420.17M
est: 396.53M (+6.0%)
|
474.80M
est: 448.69M (+5.8%)
|
490.07M
490.07M – 490.07M
+9.2% YoY
|
558.43M
558.43M – 558.43M
+13.9% YoY
|
619.14M
619.14M – 619.14M
+10.9% YoY
|
697.40M
697.40M – 697.40M
+12.6% YoY
|
| EBIT |
186.44M
est: 276.07M (-32.5%)
|
315.91M
est: 328.84M (-3.9%)
|
382.75M
est: 352.78M (+8.5%)
|
474.80M
est: 399.18M (+18.9%)
|
436.00M
436.00M – 436.00M
+9.2% YoY
|
496.81M
496.81M – 496.81M
+13.9% YoY
|
550.83M
550.83M – 550.83M
+10.9% YoY
|
620.45M
620.45M – 620.45M
+12.6% YoY
|
| Net Income |
171.31M
est: 248.03M (-30.9%)
|
292.40M
est: 332.95M (-12.2%)
|
356.52M
est: 373.62M (-4.6%)
|
463.80M
est: 478.21M (-3.0%)
|
511.94M
511.94M – 511.94M
+7.1% YoY
|
561.83M
561.83M – 561.83M
+9.7% YoY
|
625.08M
625.08M – 625.08M
+11.3% YoY
|
717.49M
717.49M – 717.49M
+14.8% YoY
|
| SGA |
171.18M
est: 181.54M (-5.7%)
|
191.50M
est: 216.25M (-11.4%)
|
212.53M
est: 231.99M (-8.4%)
|
—
est: 262.51M (-100.0%)
|
286.71M
286.71M – 286.71M
+9.2% YoY
|
326.71M
326.71M – 326.71M
+13.9% YoY
|
362.23M
362.23M – 362.23M
+10.9% YoY
|
408.01M
408.01M – 408.01M
+12.6% YoY
|
| EPS |
2.45
est: 3.54 (-30.9%)
|
4.18
est: 4.74 (-11.8%)
|
5.10
est: 5.32 (-4.1%)
|
6.60
est: 6.81 (-3.0%)
|
7.29
7.29 – 7.29
+7.1% YoY
|
8.00
8.00 – 8.00
+9.7% YoY
|
8.90
8.90 – 8.90
+11.3% YoY
|
10.21
10.21 – 10.21
+14.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-10 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-03 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
405.80M
OE per share TTM
5.80
Owner's Yield
3.77%
Maintenance CapEx ratio
4.14%
Maint CapEx / Avg PPE
55.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 58 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia ETF KSA | 0.28% | 1.85M | 0.75% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 185.9K | 0.72% |
| 3 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.05% | 295.1K | 0.55% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.05% | 166.8K | 0.74% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 46.2K | 0.56% |
| 6 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.01% | 32.1K | 0.07% |
| 7 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.01% | 57.3K | 0.44% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.01% | 668.7K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.01% | 668.7K | 0.17% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 72.3K | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
440.0K
Shares Outstanding
70.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ahmed Yousuf Mohammed Salah Jamjoom | Executive Vice Chairman | 1M | male |
| Faisal Ahmed Ibrahim Linjawi | Board Secretary | 200.0K | male |
| Anwer Mohiuddin | Chief Financial Officer | — | male |
| Hussam Salousa | Head of Business Development & Strategy and IR Director | — | — |
| Idrees Ahmed Siddiqui | Head of Manufacturing Operations | — | male |
| Mazen Al Serehi | Human Resources Director | — | — |
| Mohammed Mahmoud Jamjoom | Asst. Dir. of Public Affairs & Head of Business Operations | — | male |
| Tarek Youssef Hussein Hosni | Chief Executive Officer | — | male |
| Ammar Abdulrahman Al Attas | Head of the Legal Department & Group Legal Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4015.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
